A simple, CE-marked, whole blood test, providing long-term prognostic data that can guide clinical management in inflammatory bowel disease (Crohn’s disease and ulcerative colitis).
Award-winning PredictSURE IBD™ is the world’s first validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). PredictSURE IBD™ is based upon 10 years of extensive research on gene expression profiling of CD8+ T cells. This whole blood-based biomarker test is a major step towards personalised medicine in IBD.
PredictSURE IBD™ is an easy-to-set-up biomarker test, combined with a sophisticated, proprietary algorithm that will tell you the likely course of your newly diagnosed patients’ IBD; differentiating between an aggressive or milder form of the disease. All you need is a small blood sample from your patients (16+ years) and an on-line account for rapid, on-line reporting. With PredictSURE IBD™ you can take control of Crohn’s disease and ulcerative colitis treatment options.
*Launching in EU through 2019
Select the best treatment option for your patients with PredictSURE IBD™
- Provides additional information to support treatment choices for your patients
- Understand your adult patients’ long-term prognosis from the point of diagnosis
- Patients tested once at time of diagnosis
- Enables your patients to plan their lives based on knowledge of likely disease activity
Sign up to get the latest news
You can unsubscribe at any time using the link at the bottom of any newsletter or contacting email@example.com
Take control of Crohn’s and colitis treatment options
- Easy to run, 17-gene qPCR molecular test
- Only 2.5ml blood sample needed
- Sophisticated proprietary algorithm
- Fast turnaround
- Simple to understand, on-line reporting